HC Wainwright & Co. Maintains Buy on Enanta Pharma, Lowers Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce maintains a 'Buy' rating on Enanta Pharma (NASDAQ:ENTA) but lowers the price target from $48 to $30.
October 23, 2023 | 11:07 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Enanta Pharma's price target has been lowered from $48 to $30 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. could potentially lead to a negative sentiment among investors, which may put downward pressure on the stock price in the short term. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100